Experimental drug offered to cancer patients with severe wasting

NCT ID NCT07399015

NO_LONGER_AVAILABLE Symptom relief Sponsor: Endevica Bio Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program gives seriously ill adults with advanced pancreatic cancer and cachexia (severe weight loss and muscle wasting) access to the experimental drug mifomelatide. Patients receive a daily injection for up to 13 weeks. The goal is to provide a potential treatment option when no others are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mifomelatide
What this could lead to: If it works, this could help reduce severe weight loss and muscle wasting in people with advanced pancreatic cancer.
What could go wrong: This is an expanded access program, not a formal trial, so results are not systematically collected. It is only for patients with no other options, and the drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PDAC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Matthew-Wood syndrome pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PDAC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.